STRONGBRIDGE BIOPHARMA plc (NASDAQ:SBBP) Files An 8-K Submission of Matters to a Vote of Security Holders

STRONGBRIDGE BIOPHARMA plc (NASDAQ:SBBP) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders

On May15, 2018, Strongbridge Biopharma plc (the “Company”) held its Annual General Meeting of Shareholders (“AGM”) in Dublin,Ireland.Described below are the matters voted upon at the AGM and the number of votes for and against, abstentions and broker non-votes, as applicable.

Proposal No.1 — Re-election of ClassIII Directors – approved. Each of the ClassIII directors elected at the AGM will serve a three-year term until the conclusion of the Company’s 2021 annual general meeting and until such time as their successors are duly elected and qualified.

VotesFor

VotesAgainst

Abstain

BrokerNon- Votes

Matthew Pauls

24,537,629

50,301

1,600

11,362,650

Garheng Kong

22,577,554

2,009,376

2,600

11,362,650

Proposal No.2 — Ratification of Selection of Auditors and Authorization to Determine the Remuneration of the Auditors — approved. Shareholders were asked to vote to ratify the selection of Ernst& Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December31, 2018 and to authorize, in a binding vote, the board of directors, acting through its Audit Committee, to determine Ernst& Young’s remuneration.

Votes

For

35,937,590

Against

11,768

Abstain

2,822


About STRONGBRIDGE BIOPHARMA plc (NASDAQ:SBBP)

Strongbridge Biopharma plc, formerly Cortendo plc, is a development-stage biopharmaceutical company. The Company is engaged in advancing its product candidates through clinical development. The Company is focused on the development, in-licensing, acquisition and eventual commercialization of several complementary products and product candidates within franchises that target rare diseases. Its principal focus is to build its rare endocrine franchise, which includes product candidates for the treatment of endogenous Cushing’s syndrome and acromegaly. Its product candidate, COR-003 (levoketoconazole), is a cortisol synthesis inhibitor, indicated for the treatment of endogenous Cushing’s syndrome. It is conducting SONICS, a pivotal Phase III clinical trial for COR-003. Its product candidate, COR-005 (veldotide), is a multi-receptor targeted somatostatin analog (SSA) in Phase II clinical development for the treatment of acromegaly patients. Its product candidate also includes BP-2002.

An ad to help with our costs